Almac Clinical Services supports BioNTech by performing a range of services including secondary labelling, storage, distribution, provision of depots, temperature management through its TempEZ platform
Almac Group, the global contract development and manufacturing organisation, has welcomed the exciting news from Pfizer, and its German partner, BioNTech, that its potential COVID-19 vaccine showed better than 90% efficacy in their pivotal Phase III trial.
Almac Clinical Services is proud to support its client, BioNTech, by performing a range of services including secondary labelling, storage, distribution, provision of depots, temperature management through its TempEZ platform, drug returns and pharmacist services across the globe.
Commenting on the development, Dr Robert Dunlop, Managing Director & President, Almac Clinical Services, stated “We are delighted with their announcement that significant progress has been made in this trial. The extremely positive news that we may see a vaccine being approved for use before the end of the year is the development the world has been waiting for and we are proud to have played our part.”
Everyone at Almac wishes Pfizer and BioNTech every success as they continue their excellent work to hopefully bring this pandemic to an end
Global VP of Operations, Donna Christopher, who led the project for Almac added: “We are both proud and privileged to support this clinical study through a range services which has enabled us to play our part in the fight against COVID-19. I would like to offer our congratulations to the diligent teams at Pfizer and BioNTech for their work thus far, and to thank those within Almac for all their work in support of this. Everyone at Almac wishes Pfizer and BioNTech every success as they continue their excellent work to hopefully bring this pandemic to an end.”
In addition to the services listed above, Almac’s bespoke temperature controlled shipping solution, the Almac Pod™, is being used to transport the vaccine in the required frozen condition to investigator sites across the world. This offers a protected, optimised and dynamic solution that safeguards the product and mitigates against temperature changes throughout transit using advanced phase change technology thereby ensuring the patient receives a stable, fit-for-purpose drug which has not been compromised at any stage.
Almac Group continues its partnership with a variety of other global pharmaceutical, biotech and research institutions to support over 80 separate crucial research projects into COVID-19 treatment options. The company is supporting this urgent research need through a range of service areas, including analytical services, peptide development, expedited Interactive Response Technology (IRT) support and clinical trial manufacturing, packaging and distribution.